YS Biopharma: YS-HBV-002 vaccine granted clinical trial approval by PFDA

YS Biopharma announced that its YS-HBV-002 immunotherapeutic vaccine, designed to treat patients suffering from chronic hepatitis B virus infection, has been granted clinical trial approval by the Philippine Food and Drug Administration. In light of the approval, the company is preparing to initiate a Phase I clinical trial for YS-HBV-002 in the Philippines, which is expected to begin in June 2024.